Comparative evaluation of the new FDA approved THxID™-BRAF test with High Resolution Melting and Sanger sequencing - Wikidata - wikimedia - TriplyDB

Comparative evaluation of the new FDA approved THxID™-BRAF test with High Resolution Melting and Sanger sequencing

Comparative evaluation of the new FDA approved THxID™-BRAF test with High Resolution Melting and Sanger sequencing

http://www.wikidata.org/entity/Q34469532

about

What links BRAF to the heart function? New insights from the cardiotoxicity of BRAF inhibitors in cancer treatment Enzyme-Free Detection of Mutations in Cancer DNA Using Synthetic Oligonucleotide Probes and Fluorescence Microscopy The Future of Molecular Analysis in Melanoma: Diagnostics to Direct Molecularly Targeted Therapy.Detection of known and novel ALK fusion transcripts in lung cancer patients using next-generation sequencing approaches Addressing the challenges of applying precision oncology.

P2860

Q26782585-03E1D5C2-65AC-413A-8421-72AEFB41CE05 Q35757099-2593B0EF-6522-48CC-847B-B02835776B98 Q38620826-4BC283F4-1B9C-42EB-B9EE-41247F72B528 Q42286165-A0C70D9F-B1F6-47F6-92C8-B73912B7BE45 Q55314165-31288EF9-5C48-4C4A-BAA8-B50F71879CB2

P2860

Comparative evaluation of the new FDA approved THxID™-BRAF test with High Resolution Melting and Sanger sequencing

http://www.wikidata.org/entity/Q34469532

description

2014 nî lūn-bûn

@nan

2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Comparative evaluation of the ...... Melting and Sanger sequencing

@ast

Comparative evaluation of the ...... Melting and Sanger sequencing

@en

Comparative evaluation of the ...... Melting and Sanger sequencing

@nl

type

label

Comparative evaluation of the ...... Melting and Sanger sequencing

@ast

Comparative evaluation of the ...... Melting and Sanger sequencing

@en

Comparative evaluation of the ...... Melting and Sanger sequencing

@nl

prefLabel

Comparative evaluation of the ...... Melting and Sanger sequencing

@ast

Comparative evaluation of the ...... Melting and Sanger sequencing

@en

Comparative evaluation of the ...... Melting and Sanger sequencing

@nl

P1433

Q34469532-21FA618E-B966-4DF3-A377-3BA50C94622F

P1476

Q34469532-A8A5EFD0-AEEB-4A29-B7FC-367587F2963D

P2093

Q34469532-1D063E73-B916-4277-8103-0C9466882D40

Q34469532-4E43D24A-87FC-4C2D-820D-ADCAF070BAF2

Q34469532-BECEC0E8-D0AA-4ED7-9E46-2E553FC961E4

P2860

Q34469532-0F4B55DD-2D89-4CE4-8932-07ED38A30887

Q34469532-13BD174E-0859-4A4F-97FC-85379C1357C0

Q34469532-1F75A728-8FE6-47AA-9AA4-005CDFD0B3BA

Q34469532-2732B030-8641-4768-B1CA-81C43183002F

Q34469532-2818E655-AC0B-4934-B94C-483B0453344A

Q34469532-288EDB31-22FA-44F7-8724-76C06687FDFF

Q34469532-28ABD469-DA0F-4416-8F17-C1B260881CFF

Q34469532-33F46583-E145-4D59-BEE5-261DBBFDE04D

Q34469532-380EB6E2-2F5D-4B9D-884F-FB476C508FB5

Q34469532-4BCFC66B-FDA1-47A8-AB39-809214224955

P2888

Q34469532-9FE2ACC3-AD98-4977-A3C9-7B0AD66CFF26

P304

Q34469532-DE51131C-BD53-4BAD-BD94-DE942DFF3ECC

P31

Q34469532-B31EFB34-31A7-4244-8982-BED2CEB1BF93

P356

Q34469532-6A14884D-873F-4184-897E-75A6FE2EDF6A

P407

Q34469532-5CD198D8-F25E-4BDE-83D1-9E179A3EDBCD

P478

Q34469532-D4D6430D-8C45-48AE-9025-77C6C1B97A69

P50

Q34469532-7A65F124-B99A-462E-B917-B314AAEE4846

Q34469532-E9D19860-1F99-473F-A7CB-31D0286A14C2

P577

Q34469532-E1AB107B-D449-46AD-9575-3A0439AB5FA1

P5875

Q34469532-5AAF9C24-A5AF-46FB-9616-6479DC53384E

P6179

Q34469532-BFC6B455-5ED4-4E69-8DC5-5C17079A4B81

P698

Q34469532-9ACA8576-4BE2-4A3B-846E-28A96787A40B

P932

Q34469532-A7CEDDBD-CCF1-49CB-B82D-5E8224DAD4EE

P356

1471-2407-14-519

P1433

P1476

Comparative evaluation of the ...... Melting and Sanger sequencing

@en

P2093

Julie Marchant

http://www.w3.org/2001/XMLSchema#string

Marion Larrieux

http://www.w3.org/2001/XMLSchema#string

Valérie Costes

http://www.w3.org/2001/XMLSchema#string

P2860

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS)

Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study

Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis.

Cancer statistics, 2013

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

Improved survival with MEK inhibition in BRAF-mutated melanoma

Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032.

Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma.

P2888

1471-2407-14-519

P304

519

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1471-2407-14-519

http://www.w3.org/2001/XMLSchema#string

P407

P478

14

http://www.w3.org/2001/XMLSchema#string

P50

Jérome Solassol

P577

2014-07-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

264055249

http://www.w3.org/2001/XMLSchema#string

P6179

1000654939

http://www.w3.org/2001/XMLSchema#string

P698

25037456

http://www.w3.org/2001/XMLSchema#string

P932

4223712

http://www.w3.org/2001/XMLSchema#string